樂
樂觀
樂觀 · 25%RGC
$19.32
情境價格
$7.270
-0.185 (-2.55%)收盤時
Loading chart…
- 最高
- 7.890
- 開盤
- 7.610
- 成交量加權均價
- 7.41
- 成交量
- 171.71K
- 市值
- 45.81M
- 最低
- 7.060
- 成交金額
- 1.27M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
AI 分析 of Regencell Bioscience Holdings Ltd (RGC)
賣出Regencell Bioscience Holdings Ltd is not a good buy right now due to its significant recent decline and poor financial metrics. The current price is $7.67, with a 5-day change of -20.02% and a year-to-date decline of -62.66%. The RSI is at 34.119, indicating that the stock is oversold. The main risk is the negative earnings performance reflected in the P/E ratio of -415.58, suggesting ongoing financial struggles.
分析師評級（15）
買進
9 買進
5 持有
1 賣出
目前: 7.27
最低
—
平均
—
最高
—
估值指標
Regencell Bioscience Holdings Ltd（RGC）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 RGC 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC 常見問題 —— 由 Alphio AI 解答
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is not a good buy right now due to its significant recent decline and poor financial metrics. The current price is $7.67, with a 5-day change of -20.02% and a year-to-date decline of -62.66%. The RSI is at 34.119, indicating that the stock is oversold. The main risk is the negative earnings performance reflected in the P/E ratio of -415.58, suggesting ongoing financial struggles.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。